Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility
نویسندگان
چکیده
Seamless phase II/III clinical trials combine traditional phases II and III into a single trial that is conducted in two stages, with stage 1 used to answer phase II objectives such as treatment selection and stage 2 used for the confirmatory analysis, which is a phase III objective. Although seamless phase II/III clinical trials are efficient because the confirmatory analysis includes phase II data from stage 1, inference can pose statistical challenges. In this paper, we consider point estimation following seamless phase II/III clinical trials in which stage 1 is used to select the most effective experimental treatment and to decide if, compared with a control, the trial should stop at stage 1 for futility. If the trial is not stopped, then the phase III confirmatory part of the trial involves evaluation of the selected most effective experimental treatment and the control. We have developed two new estimators for the treatment difference between these two treatments with the aim of reducing bias conditional on the treatment selection made and on the fact that the trial continues to stage 2. We have demonstrated the properties of these estimators using simulations.
منابع مشابه
Applying a phase II futility study design to therapeutic stroke trials.
BACKGROUND AND PURPOSE Most large, randomized phase III efficacy trials of therapeutic agents in ischemic stroke have failed to find treatment benefit. We determined whether some phase III studies could have been avoided if preceded by smaller single-arm phase II studies to evaluate the futility of proceeding to phase III. METHODS To provide examples of the application of phase II methodology...
متن کاملStatistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design
BACKGROUND TNK-S2B, an innovative, randomized, seamless phase II/III trial of tenecteplase versus rt-PA for acute ischemic stroke, terminated for slow enrollment before regulatory approval of use of phase II patients in phase III. PURPOSE (1) To review the trial design and comprehensive type I error rate simulations and (2) to discuss issues raised during regulatory review, to facilitate futu...
متن کاملUnbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis‐driven selection rules
Seamless phase II/III clinical trials offer an efficient way to select an experimental treatment and perform confirmatory analysis within a single trial. However, combining the data from both stages in the final analysis can induce bias into the estimates of treatment effects. Methods for bias adjustment developed thus far have made restrictive assumptions about the design and selection rules f...
متن کاملFull title: A likelihood-based approach to early stopping in single arm phase II cancer clinical trials Short title: Likelihood-based early stopping design in single arm phase II studies
In single arm phase II trials (in cancer research in particular), Simon’s twostage design has become most commonly used due to its simplicity, its ability to allow early stopping for futility, and preservation of type I and type II errors. As an alternative, likelihood-based approaches which allow frequent looks at the data and are similar to the Bayesian adaptive designs, whereby there is not ...
متن کاملFutility stopping in clinical trials
Early stopping due to futility, also referred to as a go/nogo decision, during interim analysis has become an important feature of clinical trial designs. Current methods for futility stopping in literature are mostly based on conditional power or predictive power in conjunction with the theory of stochastic curtailment or group sequential design. They have certain drawbacks that have been note...
متن کامل